Intercept Pharmaceuticals Stock Price Down 3.7% After Insider Selling (ICPT)
Shares of Intercept Pharmaceuticals (NASDAQ:ICPT) fell 3.7% on Friday after an insider sold shares in the company, Analyst Ratings.Net reports. The stock traded as low as $342.70 and last traded at $353.00, with a volume of 427,341 shares trading hands. The stock had previously closed at $366.57.
Specifically, Director Paolo Fundaro unloaded 7,246 shares of Intercept Pharmaceuticals stock on the open market in a transaction that occurred on Friday, February 14th. The shares were sold at an average price of $375.26, for a total value of $2,719,133.96. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.
ICPT has been the subject of a number of recent research reports. Analysts at Wedbush raised their price target on shares of Intercept Pharmaceuticals from $449.00 to $493.00 in a research note on Monday. Finally, analysts at BMO Capital Markets reiterated an “outperform” rating on shares of Intercept Pharmaceuticals in a research note on Monday, January 13th. One analyst has rated the stock with a sell rating and four have given a buy rating to the stock. The stock has a consensus rating of “Buy” and an average target price of $490.83.
The stock has a 50-day moving average of $260.8 and a 200-day moving average of $104.. The company’s market cap is $6.700 billion.
Intercept Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapeutics to treat chronic liver disease.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.